DiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaHealth Care
AzacitidineMyelodysplastic SyndromesAntimetabolites, AntineoplasticLeukemia, Myelomonocytic, ChronicChromatography, Supercritical FluidCompassionate Use TrialsLeukemia, Myeloid, AcuteInjections, SubcutaneousAnemia, RefractoryConsolidation ChemotherapyInduction ChemotherapyAnemia, Refractory, with Excess of BlastsDrug ApprovalDNA MethylationDNA Modification MethylasesTreatment OutcomeSurvivalInternational AgenciesEpigenomicsUnited States Food and Drug AdministrationThalidomideDrug Administration ScheduleAntimetabolitesRemission InductionBiological AvailabilityBlood TransfusionLeukemia, MyeloidTetrazolium SaltsCytarabineAntineoplastic Combined Chemotherapy ProtocolsMaximum Tolerated DoseFatigueAcute DiseaseRetrospective StudiesHematopoietic Stem Cell TransplantationRecurrence
Browse School of Medicine | Stanford ProfilesBrowse School of Medicine | Stanford Profiles
Vitamin C and azacitidine restore the 5hmC landscape and phenotypes in TET2-mutant HSPCs. These findings offer a comprehensive ...
https://profiles.stanford.edu/browse/school-of-medicine?name=n&org=school-of-medicine/institute-for-stem-cell-biology-and-regenerative-medicine
MDS Foundation Announces Two Young Investigator Awards Supporting New Treatment Strategies at the 14th International MDS...MDS Foundation Announces Two Young Investigator Awards Supporting New Treatment Strategies at the 14th International MDS...
"My hope is that the combination of APR-246 with azacitidine in MDS patients with TP53 mutation will be a promising therapeutic ...
https://www.prweb.com/releases/mds_foundation_announces_two_young_investigator_awards_supporting_new_treatment_strategies_at_the_14th_international_mds_symposium/prweb14306326.htm
Christie M. Orschell, PhDChristie M. Orschell, PhD
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the ...
https://medicine.iu.edu/faculty/4819/orschell-christie
NIH Clinical Center: Search the Studies
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell ...
https://clinicalstudies.info.nih.gov/htmlSearchedFile.aspx?Query=Peripheral%20Retinal%20Degeneration&status=&gender=Select%20One&Inst=&age=&healthyVolunteer=0
Clinical Case of the Month - Early T-cell expansion post T-replete mismatched cord transplant with granulocytes in High-risk...Clinical Case of the Month - Early T-cell expansion post T-replete mismatched cord transplant with granulocytes in High-risk...
Soon after, he had a relapsing molecular disease which was refractory to chemotherapy including FLA-Ida and azacitidine. He had ...
https://www.ebmt.org/ebmt/news/clinical-case-month-early-t-cell-expansion-post-t-replete-mismatched-cord-transplant
Dr. Martha Arellano, MD - Atlanta, GA | HematologyDr. Martha Arellano, MD - Atlanta, GA | Hematology
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a ... Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study ... Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. ... Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. ...
https://www.doximity.com/pub/martha-arellano-md
Adult Leukemia Clinical Trials and Research | Dana-Farber Cancer InstituteAdult Leukemia Clinical Trials and Research | Dana-Farber Cancer Institute
19-606: A phase 1b/2 study of IMGN632 as monotherapy or combination with venetoclax and/or azacitidine for patients with CD123- ...
https://www.dana-farber.org/cancer-care/treatment/hematologic-oncology/programs/leukemia/clinical-trials-research
Data presented demonstrate prolonged overall | EurekAlert!Data presented demonstrate prolonged overall | EurekAlert!
... azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR). ...
https://www.eurekalert.org/news-releases/679026
Hepcinat LP 400 mg/90 mg (Sofosbuvir/Ledipasvir) - medixpillsHepcinat LP 400 mg/90 mg (Sofosbuvir/Ledipasvir) - medixpills
Save my name, email, and website in this browser for the next time I comment ...
https://www.medixpills.com/hepcinat-lp-400-mg-90-mg/
BeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical MeetingsBeiGene to Present Clinical Data on Zanubrutinib and Pamiparib at Upcoming Medical Meetings
BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China ...
https://www.einpresswire.com/article/464443550/beigene-to-present-clinical-data-on-zanubrutinib-and-pamiparib-at-upcoming-medical-meetings
Chelsea C. Pinnix | MD Anderson Cancer CenterChelsea C. Pinnix | MD Anderson Cancer Center
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor- ... Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor- ...
https://faculty.mdanderson.org/profiles/chelsea_pinnix.html
Dr Melinda TurskyDr Melinda Tursky
... in Integrative genomics identifies the molecular basis of resistance to Azacitidine therapy in Myelodysplastic Syndromes, ... 2017, Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes, ... 2016, Integrative genomics identifies the molecular basis of resistance to Azacitidine therapy in Myelodysplastic Syndromes, ...
https://www.unsw.edu.au/staff/melinda-tursky
Neutrophilic Eccrine Hidradenitis: Background, Pathophysiology, EtiologyNeutrophilic Eccrine Hidradenitis: Background, Pathophysiology, Etiology
... eccrine hidradenitis resembling acanthosis nigricans in a patient with acute myeloid leukemia associated with azacitidine and ...
https://emedicine.medscape.com/article/1070937-overview
1.62 million for rare cancer research | Newsroom | University of Adelaide1.62 million for rare cancer research | Newsroom | University of Adelaide
Phase II Trial Studying the Efficacy of Lenzilumab or High Dose Ascorbate plus Azacitidine Based on Molecular Profiling ...
https://www.adelaide.edu.au/newsroom/news/list/2020/06/29/162-million-for-rare-cancer-research
Deciphering the metabolic basis for t(11;14) multiple myeloma venetoclax sensitivity | Leukemia and Lymphoma SocietyDeciphering the metabolic basis for t(11;14) multiple myeloma venetoclax sensitivity | Leukemia and Lymphoma Society
This includes AML patients on a clinical trial of azacitidine +/- venetoclax (NCT02993523), patients with 17p deletion CLL on ...
https://www.lls.org/award/deciphering-metabolic-basis-t1114-multiple-myeloma-venetoclax-sensitivity
759 results in SearchWorks articles759 results in SearchWorks articles
Azacitidine was administered on Days 1-7 every cycle at 75 mg/m 2 /day intravenously/subcutaneously. Responses were assessed ... Venetoclax + azacitidine shows activity in patients with R/R MDS following prior HMA therapy failure and provides clinically ... Herein, we present the safety and efficacy of venetoclax + azacitidine in patients with R/R MDS. This phase 1b, open-label, ... A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. [ ...
https://searchworks.stanford.edu/articles?f%5Beds_content_provider_facet%5D%5B%5D=MEDLINE&f%5Beds_content_provider_facet%5D%5B%5D=Gale+Academic+OneFile&f%5Beds_content_provider_facet%5D%5B%5D=Academic+Search+Premier&f%5Beds_content_provider_facet%5D%5B%5D=Supplemental+Index&f%5Beds_publication_type_facet%5D%5B%5D=Academic+Journals&per_page=20&q=%22%22Robin%2C+Jacqueline%2C%22%22&search_field=author&sort=newest
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies | Haematologica Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies | Haematologica
Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine. Leuk Res. 2011; 35:S126- ...
https://haematologica.org/article/view/7731
Multiple funding proposals being considered by Pharmac - Pharmac | New Zealand GovernmentMultiple funding proposals being considered by Pharmac - Pharmac | New Zealand Government
azacitidine for treatment related myelodysplastic syndrome/acute myeloid leukaemia (widening access). Breast and blood cancer ...
https://pharmac.govt.nz/news-and-resources/news/2022-05-19-media-release-multiple-funding-proposals-being-considered-by-pharmac/
Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® ...Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® ...
894 results in SearchWorks articles894 results in SearchWorks articles
Epidemiology, Natural History, and Practice Patterns of Patients with Myelodysplastic Syndromes in 2010 in: Journal of the...
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic ... Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic ... Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic ... Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic ...
https://jnccn.org/view/journals/jnccn/9/1/article-p57.xml?rskey=Kp7ags&result=1
ORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 MillionORYZON Announces a New Financing Through a Convertible Bond Program For a Total Amount of Up To €45 Million
... iadademstat has shown encouraging safety and efficacy data in combination with azacitidine (see Salamero et al., ASH 2022 oral ...
https://wreg.com/business/press-releases/globenewswire/8983308/oryzon-announces-a-new-financing-through-a-convertible-bond-program-for-a-total-amount-of-up-to-e45-million/
Sarah Crotty - SPS - Specialist Pharmacy Service - The first stop for professional medicines adviceSarah Crotty - SPS - Specialist Pharmacy Service - The first stop for professional medicines advice
The first stop for professional medicines advice
https://www.sps.nhs.uk/author/sarah-crotty/
Index by author - January 01, 2015, 35 (1) | Anticancer Research
Azacitidine in the Front-line Treatment of Therapy-related Myeloid Neoplasms: A Multicenter Case Series (free) ...
https://ar.iiarjournals.org/content/35/1.index-by-author
Poster - Stabilis 4.0Poster - Stabilis 4.0
Stability of Azacitidine Solutions In Sterile Water For Injection. Tyono I, Law S, Charbonneau L, Walker S.E. Poster presented ... Did our fabrication process impact on azacitidine stability ? Khan A, Bernadou JM, Xyereb F, Berroneau A, Crauste-Manciet S. ...
https://stabilis.org/InfostabPublication.php?codeLangue=IT-it
Kura Oncology to Participate in Cantor Global Healthcare Conference 2023Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
... beginning with venetoclax/azacitidine and standard induction cytarabine/daunorubicin chemotherapy in NPM1-mutant and KMT2A- ...
https://www.abc4.com/business/press-releases/globenewswire/8924186/kura-oncology-to-participate-in-cantor-global-healthcare-conference-2023/
CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes:...
... and to progression to AML in the course of azacitidine treatment [10]. To our knowledge, no studies have been yet conducted ...
https://karger.com/pat/article/88/3/242/266569/CD34-Positive-Blast-Count-and-p53-Expression-in
ASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung Cancer | Cancer.NetASCO20 Virtual Research Round Up Podcast: Leukemia, Colorectal Cancer, and Lung Cancer | Cancer.Net
... discusses an early study that looked at a combination of the immunotherapy magrolimab with the chemotherapy azacitidine (Vidaza ...
https://www.cancer.net/es/node/41412
Cancer Discovery News | American Association for Cancer ResearchCancer Discovery News | American Association for Cancer Research
Gilead also nixed assessing the drug with or without azacitidine for patients with higher-risk myelodysplastic syndromes in the ...
https://aacrjournals.org/cdnews
Promoter hypermethylation influences the suppressive role of long non‑coding RNA MEG3 in the development of multiple myelomaPromoter hypermethylation influences the suppressive role of long non‑coding RNA MEG3 in the development of multiple myeloma
Wang W, Wang J, Chen M, Liang Y, LI Z, Zhang Z and Jing H: 5-Azacitidine remolds the methylation status and inhibits growth in ...
https://www.spandidos-publications.com/10.3892/etm.2020.8723